Nektar surges again as alopecia drug shows new promise in extension study

BioPharma Dive

Patients who’d seen substantial hair regrowth in the first part of Nektar s trial had a deepening treatment response, extending a comeback bid that s caused shares to skyrocket over the last year.

Clinical DataOtherRead full story